Výsledky vyhledávání - "Yvonne Voges"

YM155-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting

Autor: Martin Michaelis, Mark N. Wass, Ian Reddin, Yvonne Voges, Florian Rothweiler, Stephanie Hehlgans, Jaroslav Cinatl, Marco Mernberger, Andrea Nist, Thorsten Stiewe, Franz Rödel, Jindrich Cinatl Jr.

Publikováno v: Cancers
Cancers, Vol 12, Iss 1080, p 1080 (2020)

Survivin is a drug target and its suppressant YM155 a drug candidate mainly investigated for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d38c5c70b66e4827c343f4079d72ea91
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54471

Zobrazit plný text záznamu

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines

Autor: Yvonne Voges, Franz Rödel, Mark N. Wass, Andreas von Deimling, Fabian Weipert, Florian Rothweiler, Jaroslav Cinatl, Jindrich Cinatl, Martin Michaelis, Amara Zia-Ahmad, Frank Westermann

Publikováno v: Cancers, Vol 12, Iss 3, p 577 (2020)
Cancers
Volume 12
Issue 3

The survivin suppressant YM155 is a drug candidate for neuroblastoma. Here, we tested YM155 in 101 neuroblastoma cell lines (19 parental cell lines, 82 drug-adapted sublines). 77 cell lines displayed YM155 IC50s in the range of clinical YM155 concent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77d6fde123f5346d5f44ae77c77a6414
https://www.mdpi.com/2072-6694/12/3/577

Zobrazit plný text záznamu

Plný text ve formátu HTML

Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting

Autor: Jaroslav Cinatl, Yvonne Voges, Andrea Nist, Martin Michaelis, Ian G. Reddin, Franz Roedel, Marco Mernberger, Stephanie Hehlgans, Jindrich Cinatl, Mark N. Wass, Florian Rothweiler, Thorsten Stiewe

Survivin is a drug target and the survivin suppressant YM155 a drug candidate for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 efflux) leve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adbe7f03fda2ad7557452d07e7816108

Zobrazit plný text záznamu

Gene (HPRT) and chromosomal (MN) mutations of nickel metal powder in V79 Chinese hamster cells

Autor: Samuel Buxton, Yvonne Voges, Claudia Donath, Adriana R. Oller

Publikováno v: Mutation research.

Nickel metal is a naturally occurring element used in many industrial and consumer applications. Human epidemiological data and animal cancer bioassays indicate that nickel metal is not likely to be a human carcinogen. Yet, nickel metal is classified

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::780b7d11187f8594344aaa97e2d67398
https://pubmed.ncbi.nlm.nih.gov/32014793

Zobrazit plný text záznamu

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance

Autor: Mark N. Wass, Marco Mernberger, Martin Michaelis, Andrea Nist, Constanze Schneider, Jindrich Cinatl, Franz Rödel, Torsten Schaller, Thorsten Stiewe, Katharina Politt, Florian Rothweiler, Yvonne Voges

Publikováno v: Cell Death & Disease

Resistance formation after initial therapy response (acquired resistance) is common in high-risk neuroblastoma patients. YM155 is a drug candidate that was introduced as a survivin suppressant. This mechanism was later challenged, and DNA damage indu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f081311ed9eb71d5f0c36923acfe3f80
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45758

Zobrazit plný text záznamu

ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance

Autor: Yvonne Voges, Barbora Balónová, Martin Michaelis, Florian Rothweiler, Jindrich Cinatl, Nadine Löschmann, Barry A. Blight

Publikováno v: Oncotarget

The CDK inhibitor SNS-032 had previously exerted promising anti-neuroblastoma activity via CDK7 and 9 inhibition. ABCB1 expression was identified as major determinant of SNS-032 resistance. Here, we investigated the role of ABCB1 in acquired SNS-032

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e12af6ae17cc8742916edaf1046ad9aa

Zobrazit plný text záznamu

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents

Autor: A. von Deimling, J. Cinatl, Yvonne Voges, Franz Rödel, Rainer Breitling, Florian Rothweiler, Nadine Löschmann, Daniel Speidel, Susanne Barth, Martin Michaelis, H. Wilhelm Doerr, Bishr Agha

Publikováno v: Cell death & disease, 3(4):294. Nature Publishing Group
Cell Death & Disease

Adaptation of wild-type p53 expressing UKF-NB-3 cancer cells to the murine double minute 2 inhibitor nutlin-3 causes de novo p53 mutations at high frequency (13/20) and multi-drug resistance. Here, we show that the same cells respond very differently

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0adf9e0b18e1314ddcf611cdf88671c
https://research.rug.nl/en/publications/f013404e-63c6-4cac-a489-35fee0a3aafc

Zobrazit plný text záznamu

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs

Autor: Taravat Ghafourian, Yvonne Voges, Richard Zehner, Andreas von Deimling, Mohsen Sharifi, Nadine Löschmann, Iduna Fichtner, Frank Westermann, Jochen Meyer, Martin Michaelis, Florian Rothweiler, Jaroslav Cinatl, Kristoffer Riecken, Jindrich Cinatl

Publikováno v: Translational Oncology. 6:685-IN18

Novel treatment options are needed for the successful therapy of patients with high-risk neuroblastoma. Here, we investigated the cyclin-dependent kinase (CDK) inhibitor SNS-032 in a panel of 109 neuroblastoma cell lines consisting of 19 parental cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1389d51f640e9b6834c83d8e25806795
https://doi.org/10.1593/tlo.13544

Zobrazit plný text záznamu

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

Autor: Rainer Breitling, M. van Rikxoort, Kristoffer Weber, Elisabeth Mack, Thorsten Stiewe, Franz Rödel, A. von Deimling, Hans Wilhelm Doerr, Jindrich Cinatl, Susanne Barth, Boris Fehse, Yvonne Voges, Florian Rothweiler, Martin Michaelis, Daniel Speidel, Nadine Löschmann

Publikováno v: Cell Death & Disease
Cell death & disease, 2(12):243. Nature Publishing Group

Six p53 wild-type cancer cell lines from infrequently p53-mutated entities (neuroblastoma, rhabdomyosarcoma, and melanoma) were continuously exposed to increasing concentrations of the murine double minute 2 inhibitor nutlin-3, resulting in the emerg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40802c147063b7b81d43e999fbb73dc9
http://europepmc.org/articles/PMC3252738

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání